
Kristi Rosa
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com
Articles
FDA Grants Ivosidenib Plus Azacitidine Approval for Newly Diagnosed AML With IDH1 Mutations
May 25, 2022
Article
Ivosidenib plus azacitidine received FDA approval for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) harboring IDH1 mutations.
FDA Grants Azacitidine Approval For Pediatric Patients With Myelomonocytic Leukemia
May 23, 2022
Article
Azacitidine (Vidaza) is now FDA approved for pediatric patients with newly diagnosed myelomonocytic leukemia.
Patients With Advanced Prostate Cancer on Relugolix Experience Manageable Toxicity Levels
May 18, 2022
Article
Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, demonstrated a manageable toxicity profile for patients with advanced prostate cancer.
FDA Approves Trastuzumab Deruxtecan for Unresectable or Metastatic HER2+ Breast Cancer
May 05, 2022
Article
Fam-trastuzumab deruxtecan-nxki is now an FDA-approved regimen for the treatment of patients with unresectable or metastatic HER2-positive breast cancer.
FDA Launches Priority Review of Darolutamide for Metastatic Hormone-Sensitive Prostate Cancer
May 04, 2022
Article
The FDA has granted a priority review designation to darolutamide plus docetaxel for patients with metastatic hormone-sensitive prostate cancer.
Tislelizumab/Chemo Combo Extends Progression-Free Survival in Recurrent or Metastatic Nasopharyngeal Cancer
April 24, 2022
Article
The phase 3 RATIONALE 309 trial highlighted the combined efficacy of tislelizumab and chemotherapy in the frontline treatment of patients with recurrent or metastatic nasopharyngeal cancer.
Tiragolumab/Atezolizumab Fails to Improve PFS in Extensive-Stage SCLC
April 09, 2022
Article
An update from the phase 3 SKYSCRAPER-02 trial found that tiragolumab to atezolizumab did not significantly improve progression-free survival in extensive-stage small cell lung cancer.
Selpercatinib Shows Promise in Advanced RET Fusion-Positive NSCLC
April 05, 2022
Article
Patients with metastatic RET fusion–positive non–small cell lung cancer experienced encouraging responses with selpercatinib.
Axi-Cel Snags FDA Approval for Second-Line LBCL
April 04, 2022
Article
Axicabtagene ciloleucel is now FDA-approved for the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.
Pretreatment With Temozolomide, Immunotherapy Combo Elicits Encouraging Responses in MSS and MGMT-Silenced mCRC
April 03, 2022
Article
The addition of temozolomide to a low-dose treatment plan of ipilimumab and nivolumab extended progression-free survival among patients with metastatic colorectal cancer.